TITLE

Pacritinib Reduces Splenomegaly in Myelofibrosis Patients

PUB. DATE
January 2012
SOURCE
Drug Discovery & Development;Jan2012, Vol. 15 Issue 1, p26
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the Phase 2 study of S*BIO Pte. Ltd. on its JAK2 inhibitor pacritinib (SB1518) which indicates that pacritinib significantly reduces splenomegaly in patients with myelofibrosis.
ACCESSION #
70639317

 

Related Articles

  • European Haematology Association.  // BioWorld Today;6/15/2010, Vol. 21 Issue 114, p4 

    The article reports on the Phase I/II dose escalation trial of S*BIO Pte. Ltd.'s oral JAK2 inhibitor SB1518 which drew positive safety, tolerability and pharmacokinetic/pharmacodynamic findings.

  • JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib. Koehler, Anne; Hubert, Karolin; Lange, Thoralf; Siebolts, Udo; Wickenhauser, Claudia; Gopalakrishna, Prashanth; Niederwieser, Dietger; Monecke, Astrid; Al-Ali, Haifa; Al-Ali, Haifa Kathrin // Annals of Hematology;Nov2015, Vol. 94 Issue 11, p1929 

    The article presents a case study of a 50-year-old Caucasian man with histologically proven primary myelofibrosis, who achieved clinical, histopathologic and JAK2V617F molecular remissions under the treatment of ruxolitinib. Improvement in constitutional symptoms and spleen volume reduction were...

  • Correction.  // BioWorld Today;4/6/2007, Vol. 18 Issue 67, p2 

    A correction to the misidentification of the location of the headquarters of the company S*BIO Pte. Ltd. that was published in the April 4, 2007 issue is presented.

  • S*BIO Adds $26M for Phase II Cancer Studies.  // Bioworld Week;10/27/2008, Vol. 16 Issue 43, p3 

    The article reports on the $26 million funds raised by S☆BIO Pte. Ltd. in 2008. The company raised $26 million in a Series B financing round, which will be used mainly to move its lead compound for cancer, SB939 and SB1518, into Phase II trials. SB939, currently in Phase I testing in both...

  • S*BIO/UNIVERSITY OF SINGAPORE PARTNER ON TUMOR BIOAMARKER.  // Worldwide Biotech;Jul2007, Vol. 19 Issue 7, p7 

    The article focuses on the two-year research partnership forged by S*BIO Pte Ltd. with the National University Hospital-National University of Singapore Tissue Repository (NUH-NUS TR). The partnership is aimed at conducting biomarker research and at evaluating the responsiveness of tumors to the...

  • S*BIO INITIATES CLINICAL TRIAL OF NOVEL ANTI-CANCER DRUG.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p1 

    The article reports that the clinical trial of the novel anti-cancer drug was initiated by the S*BIO Pte Ltd. in Singapore. The SB939 is a histone deacetylase (HDAC) inhibitor which is a targeted anti-cancer therapeutics. The SB939 Phase I trial was conducted to determine its pharmacokinetic and...

  • S*BIO ADVANCES JAK2 INHIBITOR SB1518 INTO PHASE 1/2 TRIAL.  // Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p4 

    The article reports on the initiation of a Phase ½ clinical trial of JAK2-selective kinase inhibitor drug SB1518 in patients with chronic idiopathic myelofibrosis (CIMF) in Australia in January 2009. The trial, launched by Singaporean company S*BIO Pte Ltd., will be conducted in two phases....

  • CLINIC ROUNDUP.  // BioWorld Today;9/19/2008, Vol. 19 Issue 183, p7 

    This section offers news briefs on the pharmaceutical industry. Avigen Inc. has completed the double-blind portion of its Phase IIb trial for AV650 used in the treatment of spasticity linked to multiple sclerosis. Positive results were reported by Incyte Corp. from Phase IIa trials of topical...

  • S*BIO Regains JAK2 Inhibitors After Onyx Rejects Option. Wall, Tom // BioWorld Today;5/5/2011, Vol. 22 Issue 87, p1 

    The article reports that Onyx Pharmaceuticals Inc. and S*BIO Pte. Ltd. have decided to restructure their agreement on developing JAK2 inhibitors ONX 0803/SB1518 and ONX 0805/SB1578. The decision came after Onyx decided not to exercise its option to develop and commercialize the compounds. This...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics